Article Sidebar

PDF
Date Published: 08/06/2021
Abstract Views: 171
Views PDF: 173
DOI: https://doi.org/10.51298/vmj.v500i1.315
Issue
Vol. 500 No. 1 (2021)
Section
Các bài báo
How to Cite
Thị Thùy, P. ., Thị Thu Hương, B. ., & Thị Hương, N. . (2021). RELATIONSHIP BETWEEN VKORC1-1639G>A, 1173C>T, CYP2C9*3 AND ACENOCOUMAROL DOSAGE IN CARDIOVASCULAR DISEASE PATIENTS IN THAI NGUYEN CENTRAL HOSPITAL. Vietnam Medical Journal, 500(1). https://doi.org/10.51298/vmj.v500i1.315

RELATIONSHIP BETWEEN VKORC1-1639G>A, 1173C>T, CYP2C9*3 AND ACENOCOUMAROL DOSAGE IN CARDIOVASCULAR DISEASE PATIENTS IN THAI NGUYEN CENTRAL HOSPITAL

Phạm Thị Thùy, Bùi Thị Thu Hương, Nguyễn Thị Hương

Main Article Content

Abstract

In patients with cardiovascular diseases at high risk of thrombosis, the use of anticoagulants such as acenocoumarol is essential. There are many factors influencing the dose variation between individual patients, including genetic traits. Therefore, this study was carried out with the aim of determining the association between the genetic polymorphisms VKORC1-1639G>A, 1173C>T and CYP2C9*3 with the dose of acenocoumarol in cardiovascular patients at Thai Nguyen Central Hospital. Method: Determination of allele frequency, genotype VKORC1-1639G>A, 1173C>T and CYP2C9*3 by PCR-CTPP technique and genetic sequencing. Results: The rates of allele variation of VKORC1-1639G>A, 1173C>T and CYP2C9*3 were 0.911, 0.001 and 0.023, respectively. There was an association between, age, BMI and gene polymorphism VKORC1-1639G>A, 1173C>T and acenocoumarol dose in patients with cardiovascular diseases at Thai Nguyen Central Hospital (p <0 ,05).

Article Details

Keywords

Acenocoumarol, VKORC1, CYP2C9 polymorphisms

References

1. Krishna Kumar D, Madhan S, Balachander J, et al (2013). Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients. Thromb Res, 131(4), 363–367.
2. Ajmi M, Omezzine A, Achour S, et al (2018). Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population. Eur J Clin Pharmacol, 74(6), 711–722.
3. Buzoianu A.D, Militaru F.C, Vesa S.C, et al (2013). The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population. Blood Cells Mol Dis, 50(3), 166–170.
4. Elkhazraji A, Bouaiti E.A, Boulahyaoui H, et al (2018). Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients. Drug Discoveries & Therapeutics, 9.
5. Pham T.T, Nhung P.T.H, Ta V.T, et al (2019). VKORC1 and CYP2C9*3 Polymorphisms and Their Impacts to Acenocoumarol Dosage in Vietnamese Heart Valve Replacement Patients†. 10.
6. Pop T.R, Vesa Ş.C, Trifa A.P, et al (2013). An acenocoumarol dose algorithm based on a South-Eastern European population. Eur J Clin Pharmacol, 69(11), 1901–1907.
7. Varnai R, Sipeky C, Nagy L, et al (2017). CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary. Environ Toxicol Pharmacol, 56, 282–289.